Investigating the role of Thrombospondin-1 in heart failure with preserved ejection fraction.
Thrombospondin-1's role in heart failure with preserved ejection fraction (HFpEF)
This study is looking at how a protein called Thrombospondin-1 affects heart failure with preserved ejection fraction (HFpEF), which mainly impacts women after menopause, to find new ways to treat the condition by understanding how it changes the heart.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11175792 on NIH RePORTER |
What this research studies
This research focuses on understanding how Thrombospondin-1 (TSP-1) contributes to heart failure with preserved ejection fraction (HFpEF), a condition that primarily affects women after menopause. The study aims to identify the mechanisms behind the structural changes in the heart associated with HFpEF, particularly how TSP-1 interacts with other proteins and growth factors to influence cardiac remodeling. By exploring these pathways, the research seeks to develop targeted therapies that address the underlying causes of HFpEF rather than just managing symptoms. Patients may be involved in trials that assess the effects of interventions aimed at modifying TSP-1 activity.
Who could benefit from this research
Good fit: Ideal candidates for this research are postmenopausal women who are experiencing symptoms of heart failure with preserved ejection fraction.
Not a fit: Patients with heart failure due to other causes or those who are not postmenopausal may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the mechanisms of heart failure with preserved ejection fraction, improving outcomes for affected patients.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in heart failure, suggesting that this approach may yield beneficial results.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Steppan, Jochen — Johns Hopkins University
- Study coordinator: Steppan, Jochen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.